Lee Sung Uk1, Kim Young Ae2, Yoon Young-Ho3, Kim Yeon-Joo1,4, Lim Myong Cheol4,5,6, Park Sang-Yoon4, Seo Sang-Soo4, Park Ji Eun1, Kim Joo-Young7,8,9. 1. Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea (Republic of). 2. Cancer Policy Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea (Republic of). 3. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea (Republic of). 4. Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea (Republic of). 5. Gynecologic Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea (Republic of). 6. Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea (Republic of). 7. Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea (Republic of). jooyoungcasa@ncc.re.kr. 8. Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea (Republic of). jooyoungcasa@ncc.re.kr. 9. Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, 410-769, Goyang, Gyeonggi, Korea (Republic of). jooyoungcasa@ncc.re.kr.
Abstract
PURPOSE: To evaluate the global health status of long-term cervical cancer survivors (LCCS) who survived for more than 4 years after curative radiation treatment (RT). PATIENTS AND METHODS: Medical records of 562 women treated with RT in our institution between 2003 and 2010 were reviewed. Excluding 259 women who died of disease or were lost to follow-up, disease status and late morbidities were evaluated in 303 LCCS. Quality of life (QoL) was analyzed in 168 LCCS using a questionnaire from the European Organization for the Research and Treatment of Cancer, and the results were compared with an age-matched healthy Korean female population. RESULTS: Median follow-up was 6.8 years (range 4.1-12.5 years). There were 14 deaths (7 cancer specific) and 14 recurrences (5 local recurrences and 9 distant metastases). The median time to recurrence was 6.0 years (range 4.1-8.2 years). Grade ≥2 late toxicities were frequently observed in the bladder (19%) and small/large intestine (15%). Multivariate analysis revealed a higher rate of late toxicity in patients aged ≥51 years at diagnosis (small/large intestine: hazard ratio, HR, 2.5 [1.2-5.5]; bladder: HR 2.4 [1.3-4.5]; and bone: HR 4.3 [1.2-15.8]) than patients aged <51 years. Compared to the general population, LCCS exhibited a significantly higher rate of body image concerns, sexual dysfunction, lymphedema, and peripheral neuropathy. CONCLUSION: New recurrences occurred in 5% of LCCS and grade ≥2 treatment-related morbidities were present in 33%. A significant proportion of LCCS also showed decreased cervical-cancer-specific QoL. These results suggest the need for long-term surveillance and follow-up care for LCCS.
PURPOSE: To evaluate the global health status of long-term cervical cancer survivors (LCCS) who survived for more than 4 years after curative radiation treatment (RT). PATIENTS AND METHODS: Medical records of 562 women treated with RT in our institution between 2003 and 2010 were reviewed. Excluding 259 women who died of disease or were lost to follow-up, disease status and late morbidities were evaluated in 303 LCCS. Quality of life (QoL) was analyzed in 168 LCCS using a questionnaire from the European Organization for the Research and Treatment of Cancer, and the results were compared with an age-matched healthy Korean female population. RESULTS: Median follow-up was 6.8 years (range 4.1-12.5 years). There were 14 deaths (7 cancer specific) and 14 recurrences (5 local recurrences and 9 distant metastases). The median time to recurrence was 6.0 years (range 4.1-8.2 years). Grade ≥2 late toxicities were frequently observed in the bladder (19%) and small/large intestine (15%). Multivariate analysis revealed a higher rate of late toxicity in patients aged ≥51 years at diagnosis (small/large intestine: hazard ratio, HR, 2.5 [1.2-5.5]; bladder: HR 2.4 [1.3-4.5]; and bone: HR 4.3 [1.2-15.8]) than patients aged <51 years. Compared to the general population, LCCS exhibited a significantly higher rate of body image concerns, sexual dysfunction, lymphedema, and peripheral neuropathy. CONCLUSION: New recurrences occurred in 5% of LCCS and grade ≥2 treatment-related morbidities were present in 33%. A significant proportion of LCCS also showed decreased cervical-cancer-specific QoL. These results suggest the need for long-term surveillance and follow-up care for LCCS.
Entities:
Keywords:
Gynecology; Quality of life; Side effects; Survival; Toxicity
Authors: Lari Wenzel; Israel DeAlba; Rana Habbal; Brenda Coffey Kluhsman; Diane Fairclough; Linda U Krebs; Hoda Anton-Culver; Ross Berkowitz; Noreen Aziz Journal: Gynecol Oncol Date: 2005-05 Impact factor: 5.482
Authors: John M Kirwan; Paul Symonds; John A Green; Jayne Tierney; Mandy Collingwood; Christopher J Williams Journal: Radiother Oncol Date: 2003-09 Impact factor: 6.280
Authors: Ida J Korfage; Marie-Louise Essink-Bot; Floortje Mols; Lonneke van de Poll-Franse; Roy Kruitwagen; Marjolein van Ballegooijen Journal: Int J Radiat Oncol Biol Phys Date: 2008-09-25 Impact factor: 7.038
Authors: Anil K Chaturvedi; Eric A Engels; Ethel S Gilbert; Bingshu E Chen; Hans Storm; Charles F Lynch; Per Hall; Froydis Langmark; Eero Pukkala; Magnus Kaijser; Michael Andersson; Sophie D Fosså; Heikki Joensuu; John D Boice; Ruth A Kleinerman; Lois B Travis Journal: J Natl Cancer Inst Date: 2007-10-30 Impact factor: 13.506
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Maaike J Berveling; Johannes A Langendijk; Jannet C Beukema; Marian J E Mourits; Anna K L Reyners; Elisabeth Pras Journal: J Gynecol Oncol Date: 2011-09-28 Impact factor: 4.401
Authors: Christina M Wilson; Deborah B McGuire; Beth L Rodgers; R K Elswick; Sarah M Temkin Journal: Cancer Nurs Date: 2021 Sep-Oct 01 Impact factor: 2.592